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The complement system has been implicated as a major 
factor in the development and progression of age-related 
macular degeneration (AMD) [1,2]. Genome-wide associ-
ated studies (GWASs) have shown that single nucleotide 
polymorphisms (SNPs) in complement regulators Factor H 
and Factor I and complement proteins C3, C2, and Factor B 
are genetic risk factors for AMD [2-4]. An important GWAS 
finding is the Y402H SNP of Factor H, in which a tyrosine 
in position 402 is replaced by a histidine, resulting in the 
H402 risk variant [5-8]. It has been hypothesized that in the 
presence of the risk variant the complement system is under-
regulated, thus contributing to inflammation when activated 
locally in association with drusen deposits at the RPE-Bruch’s 
membrane interface [4,9]. Although drusen formation, a char-
acteristic accumulation of protein and membranous debris in 
AMD tissues, may not be initiated by the complement system, 
an over-activated (under-regulated) complement system 
has been shown to contribute to drusen accumulation and 
exacerbation of AMD pathology [4,10]. Therefore, inhibition 
of the complement system is a promising strategy to slow the 
progression of AMD pathogenesis.
Currently, AMD is treated using monoclonal antibody–
based therapies targeting vascular endothelial growth factor 
(VEGF), which stimulates choroidal neovascularization and 
induces vascular leakage [11]. However, such therapies are 
effective in the wet (neovascular) form of AMD, associ-
ated with vessel rupture and local bleeding, but not in dry 
(atrophic) form of AMD that is characterized by the accu-
mulation of drusen deposits and RPE atrophy. Compstatin 
family peptides were initially developed as inhibitors of 
complement-mediated autoimmune and inf lammatory 
diseases, using phage display, functional, structural, compu-
tational studies (see review [12], and references therein). They 
became attractive low-molecular mass complement inhibi-
tors for the treatment of AMD soon after the 2005 genomics 
studies implicated complement in AMD (see review [13], 
and references therein). Compstatin family peptides func-
tion by binding to complement protein C3 and sterically 
inhibiting the cleavage of C3 to C3a and C3b by convertase, 
thus impeding the formation of the chemotactic fragment 
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Purpose: To redesign a complement-inhibiting peptide with the potential to become a therapeutic for dry and wet age-
related macular degeneration (AMD).
Methods: We present a new potent peptide (Peptide 2) of the compstatin family. The peptide is developed by rational 
design, based on a mechanistic binding hypothesis, and structural and physicochemical properties derived from mo-
lecular dynamics (MD) simulation. The inhibitory activity, efficacy, and solubility of Peptide 2 are evaluated using a 
hemolytic assay, a human RPE cell–based assay, and ultraviolet (UV) absorption properties, respectively, and compared 
to the respective properties of its parent peptide (Peptide 1).
Results: The sequence of Peptide 2 contains an arginine-serine N-terminal extension (a characteristic of parent Peptide 
1) and a novel 8-polyethylene glycol (PEG) block C-terminal extension. Peptide 2 has significantly improved aqueous 
solubility compared to Peptide 1 and comparable complement inhibitory activity. In addition, Peptide 2 is more effica-
cious in inhibiting complement activation in a cell-based model that mimics the pathobiology of dry AMD.
Conclusions: We have designed a new peptide analog of compstatin that combines N-terminal polar amino acid exten-
sions and C-terminal PEGylation extensions. This peptide demonstrates significantly improved aqueous solubility and 
complement inhibitory efficacy, compared to the parent peptide. The new peptide overcomes the aggregation limitation 
for clinical translation of previous compstatin analogs and is a candidate to become a therapeutic for the treatment of 
AMD.
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C3a, the opsoninizing fragment C3b, and the propagation of 
the complement system through the common pathway that 
ultimately results in the assembly of C5b-9n (also known as 
the membrane attack complex, MAC), a protein complex that 
forms pores on cell membranes.
One compstatin analog underwent clinical trials for 
AMD, and although the analog did not raise safety concerns, 
it did not show therapeutic efficacy. It is postulated that was 
likely the effects of molecular aggregation that resulted in 
the formation of gel-like structures [14,15] and an associ-
ated loss of functionality. This analog had been optimized 
over several years to have higher binding affinity than the 
original compstatin analogs by introducing a replacement of 
valine at position 4 with an aromatic amino acid, tyrosine 
[16,17] or tryptophan [18], and subsequently with methylated 
tryptophan [19]. The latter modification also increased the 
hydrophobic character of the peptide and presumably contrib-
uted to its aggregation in the aqueous ocular environment. 
Additional compstatin analogs are currently in clinical trials 
for various complement-mediated diseases [20].
Recent studies have focused on increasing the solubility 
of compstatin peptides, using structure-based rational design, 
computational modeling, and optimization [21,22]. These 
studies have identified several analogs with N-terminal 
extensions that have inhibitory activities similar to those of 
the most potent analogs and have higher aqueous solubili-
ties. Increased solubility was made possible by introducing 
two polar amino acid extensions at the N-terminus. In one 
analog, an arginine at sequence position −1 not only contrib-
uted to solubility but was also shown by molecular dynamics 
simulations to form a salt bridge with a glutamic acid in C3, 
thus contributing to binding affinity as well [21,22]. In this 
study, we used a potent analog with arginine at position −1 
and serine at position 0 [22], Peptide 1 here (or Peptide 9 in 
[22]), as a template to further increase solubility by incor-
porating two polar amino acid extensions and polyethylene 
glycol (PEG) blocks at the C-terminus. We demonstrate the 
high potency and high solubility of the new analog, using in 
vitro functional and solubility assays. We also demonstrate 
the efficacy of this peptide to inhibit complement activation 
in a human RPE cell–based assay that mimics AMD patho-
physiology. We show that this PEGylated compstatin analog 
has significant promise as a therapeutic for AMD.
METHODS
Peptide synthesis: Compstatin Peptides 1 and 2 (Table 1) 
were synthesized by WuXi AppTec (Shanghai, China). 
Peptide 2 has eight PEG blocks attached at the backbone of 
the C-terminal amino acid. Both peptides were cyclized by a 
disulfide bridge between the two cysteine amino acids, and 
they were acetylated at the N-terminus and amidated at the 
C-terminus. The peptides had >95% purity, as determined 
with high-performance liquid chromatography (HPLC) and 
mass spectrometry (MS).
Hemolytic assay: Rabbit erythrocytes (Complement Tech-
nology, Inc., Tyler, TX) were washed with PBS (1X; 3.8 mM 
monobasic NaH2PO4, 16.2 mM dibasic Na2HPO4, 150 mM 
NaCl, pH 7.4) and then resuspended in a veronal-buffered 
saline solution (VBS 1X; 72.8 mM NaCl, 0.9 mM sodium 
barbital, 1.5 mM barbituric acid, pH 7.4) containing 5 mM 
MgCl2 and 10 mM EGTA (VBS-MgEGTA). Twofold serial 
dilutions of the compstatin analogs were performed in 
round-bottom 96-well plates and then further diluted in 
VBS-MgEGTA. Normal human serum (NHS; Complement 
Technology, Inc.) diluted in VBS-MgEGTA was added to 
each well followed by incubation at room temperature for 15 
min. Subsequently, 30 μl of rabbit erythrocytes at a concen-
tration of 1.25 × 108 cells/ml were added to each well. Posi-
tive controls for lysis consisted of erythrocytes in deionized 
water and erythrocytes in NHS diluted with VBS-MgEGTA. 
Negative controls for lysis consisted of erythrocytes in VBS-
MgEGTA and erythrocytes in NHS diluted in VBS-EDTA 
(20 mM EDTA). Next, plates were incubated at 37 °C for 20 
min, and then ice-cold VBS containing 50 mM EDTA was 
added to each well to quench hemolytic reactions. The plates 
were centrifuged at 1000 ×g for 5 min, and the supernatant 
was diluted 1:1 with deionized water in flat-bottom 96-well 
plates. Absorbance was measured spectrophotometrically at 
405 nm to quantify lysis.
Table 1. PePTide sequences.
Peptide Sequence Molecular mass
1 Ac- RSI[CVWQDWGAHRC]T -NH2 1856
2 Ac- RSI[CVWQDWGAHRC]T-PEG8 -NH2 2279
Peptide 1 is a positive control with a two-polar amino acid N-terminal extension [22]. Peptide 2 is a new 
design that contains an 8-PEG block backbone extension. Brackets denote disulfide bridge cyclization 
between the two cysteine amino acids. Ac: acetylation blocking group; NH2: amidation blocking group.
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Apparent solubility measurements: Compstatin analogs were 
dissolved in PBS at pH 7.4 to concentrations of 10, 7.5, and 
5 mg/ml. At each concentration point, the peptide solutions 
were shaken on a vortex mixer for 30 s and then centrifuged 
at 13,000 ×g for 5 min. The supernatant was collected and 
measured 5 times spectrophotometrically at 280 nm. Optical 
densities were converted into concentrations according to the 
Beer-Lambert law. An extinction coefficient of 11,125 M−1 
cm−1 was used for each compstatin analog as each peptide 
contains two tryptophan amino acids (tryptophan extinction 
coefficient being 5562.5 M−1 cm−1).
RPE cell culture: The in vitro model of drusen biogenesis 
was used as previously reported [23] and used in assessing 
the efficacy of compstatin peptides [21,22]. Briefly, RPE 
cells from human fetal eyes, obtained as previously described 
[24], were used within the second passage were grown on 
laminin-coated porous inserts (Millipore, Billerica, MA) 
in Miller medium [25] supplemented with 5% fetal bovine 
serum (FBS; HyClone, Logan, UT) at 37 °C and 5% CO2 in 
a humidified incubator. After culturing for 2–3 months, the 
cells were rinsed with PBS and treated with Miller medium 
containing either 5% FBS (negative control) or 10% NHS 
without or with the inhibitory peptides (2 μM). The choice 
of the 2 µM dose for this assay was based on the intent to 
use double the IC50 concentration, which was determined to 
be about 1 µM. All inhibitory peptides were premixed with 
NHS on a rocker at room temperature for 30 min and then 
warmed to 37 °C before being added to the RPE cell cultures 
for 24 h. Next, the cells were rinsed with PBS, fixed in 4% 
paraformaldehyde (PFA; Electron Microscopy Sciences, 
Hatfield, PA) for 20 min, and stored in 0.4% PFA until use in 
the immunofluorescence assays.
Immunofluorescence of sub-RPE deposits: Basal deposits 
formed by the RPE cultures were visualized with immuno-
fluorescence, as previously described [21,23]. Briefly, porous 
inserts were excised with a scalpel, cut into approximate 
4 mm2 pieces, and rinsed several times with PBS. Next, one 
half of all RPE culture inserts were embedded in 10% (w/v) 
agarose (Fisher, Waltham, MA) and sectioned at 100 μm using 
a vibratome, while the other half was subjected to decellular-
ization (to remove the RPE monolayer) using our previously 
reported protocol [26,27]. Briefly, to obtain decellularized 
inserts, confluent RPE monolayers were incubated in Ca2+, 
Mg2+-free PBS for 30 min before treatment with a mild deter-
gent composed of 1% Triton X-100 and 80 mM ammonium 
hydroxide for 5 min. The decellularized inserts were next 
rinsed in PBS three times before fixation with 4% PFA (20 
min). Next, the vibratome sections and decellularized inserts 
were blocked with 5% donkey serum in PBS containing 0.5% 
BSA and 0.1% Triton X-100 (overnight at 4 °C) and labeled 
with mouse anti-C5b-9 (AbCam, Cambridge, MA; overnight 
at 4 °C or 2 h at room temperature), followed by labeling (2 
h at room temperature) with Alexa Fluor 488-labeled anti-
mouse immunoglobulin G (IgG; Life Technologies, Carlsbad, 
CA). The immunolabeled decellularized inserts were directly 
mounted in Fluoromount (Sigma, St. Louis, MO) while the 
sections were counterstained with 4',6-diamidino-2-phenyl-
indole (DAPI), a nuclear stain, before mounting.
Confocal imaging and analysis: Immunolabeled RPE sections 
and decellularized culture inserts were imaged using a Leica 
(Leica Microsystems, Buffalo Grove, IL) SP5 confocal micro-
scope. Single-plane images from multiple non-overlapping 
areas were acquired using a 63× objective, and C5b-9n (MAC) 
immunofluorescence signals were quantified using ImageJ 
(National Institute of Health, Bethesda, MD), as we have 
previously reported [21]. Briefly, the color thresholding tool 
of ImageJ was used to analyze the intensity of C5b-9n associ-
ated fluorescence. Here, the upper intensity threshold was set 
such that the entire deposit area was selected for fluorescence 
intensity measurement while the lower intensity threshold 
was set to eliminate any background fluorescence. For statis-
tical analysis, fluorescence intensity measurements of C5b-9n 
were averaged from multiple images and normalized with 
respect to the number of RPE nuclei per image (for vibratome 
sections) or the total image area (for decellularized whole 
mount samples) and then expressed as a percentage of the 
corresponding fluorescence intensities from samples exposed 
to NHS in the absence of any inhibitory peptide (positive 
control). All data were obtained from multiple images (n≥9) 
of fhRPE cells from the same donor and expressed as mean ± 
standard error of the mean (SEM). Statistical significance was 
determined using ANOVA (ANOVA), followed by Tukey’s 
post-hoc analysis (Instat GraphPad Software Inc., La Jolla, 
CA). A p value of less than 0.05 was considered statistically 
significant.
Structural modeling: A structural model of the eight-linked 
PEG blocks was generated using MOLDRAW [28] and then 
attached to a structural model of Peptide 1 using structure 
editing tools in Chimera [29], to generate a structural model 
of Peptide 2. The structural model of Peptide 1 was derived 
from molecular dynamics simulations, based on the crystal 
structure of bound compstatin [30]. CHARMM parameters 
and topologies [31] were used and modified to incorporate 
the peptide-like bond between PEG8 and Peptide 1. Modifica-
tions were rationally chosen based on existing amino acid 
parameters and topologies. Angles and dihedral angles that 
did not have a counterpart in existing CHARMM parameters 
and topologies were generated using SwissParam [32].
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Molecular dynamics simulation: An explicit-solvent molec-
ular dynamics simulation was performed, for 90 ns, using 
as the initial structure the modeled Peptide 2 structure. The 
explicit-solvent environment consisted of a water box and 
counterions to represent the solvated environment of the 
biomolecular system. The peptide was solvated in a TIP3P 
water box with dimensions of 75 × 57 × 67 Å, and charges 
were neutralized with sodium and chloride counterions at 
150 mM. The TIP3P water model is a standard 3-site water 
model used in explicit solvent MD simulations that describes 
the configuration of the water molecules (rigidity/flexibility), 
polarization, and interactions in the simulation. Preparation 
steps (minimization, heating, and equilibration) were carried 
out to remove strain in the system, to heat the system to the 
desired temperature, and to relax the system prior to the 
production simulation dynamics, as described in a previous 
study [33]. Following 25,000 steps of conjugate gradient 
energy minimization, the system was heated from 0 to 300 K 
in 62 ps with protein atoms constrained to post-minimization 
positions. Subsequently, the system was equilibrated through 
five stages for 50 ps per stage. Force constants of 41.83, 
20.92, 8.368, and 4.184 kJ/mol/Å2 were applied during the 
first four stages, respectively, to harmonically constrain all 
protein atoms to their post-minimization positions. During 
the fifth stage of equilibration, only the backbone atoms 
were harmonically constrained using a force constant of 
4.184 kJ/mol/Å2. Following equilibration, a production run 
was performed for 90 ns with periodic boundary conditions, 
SHAKE algorithm, 2 fs time steps, Langevin pressure and 
temperature controls, and particle-mesh Ewald electrostatics. 
The molecular dynamics trajectory (9,000 frames) was clus-
tered using the root-mean-square deviation (RMSD) of the 
backbone or alpha carbon atoms of Peptide 2, and a repre-
sentative structure from the highest-populated clusters was 
identified and depicted for molecular graphics visualization.
RESULTS
The objective of this study is to optimize the aqueous solu-
bility while maintaining the binding affinity of Peptide 
1 (Table 1), our compstatin peptide that previously had 
the most promise to become a therapeutic for AMD. Our 
previous studies [21,22] focused on improving the solubility 
of the peptide that underwent clinical studies for AMD, with 
sequence Ac-I[CV(meW)QDWGAHRC]T-NH2 [13]. This 
peptide had high aggregation propensity in aqueous solu-
tion, attributed to the peptide’s reduced solubility compared 
to other less potent compstatin analogs [21]. It was first shown 
that adding polar dipeptides at the N-terminus (positions −1 
and 0) improved solubility while maintaining potency, with 
the peptide Ac-RSI[CV(meW)QDWGAHRC]T-NH2 was 
the most efficacious in the human RPE cell–based assay 
described in Methods (Peptide VI in [21]). In a subsequent 
study, it was deemed necessary to eliminate the methyl group 
from tryptophan at position 4 to further improve solubility, 
without compromising potency, resulting in the sequence of 
Peptide 1 (Peptide 9 in [22]).
To achieve our objective, we redesigned Peptide 1 by 
adding PEG block extensions at the C-terminus (Peptide 2; 
Table 1). The choice of the extension at the C-terminus of 
Peptide 2 was guided by the results of molecular dynamics 
simulations, which had shown that the C-terminus of comp-
statin points away from the C3-binding site toward the solvent 
[21,34]. Thus, we reasoned that such extensions would not 
interfere with the binding interface between the compstatin 
analog and C3. Peptide 2 contains eight PEG blocks attached 
at the peptide backbone in the C-terminus. The choice of 
PEG blocks was guided by earlier surface plasmon resonance 
(SPR) and enzyme-linked immunosorbent assay (ELISA) 
data, which had shown that PEGylated compstatin peptides 
had higher solubility compared to non-PEGylated peptides 
with the same sequence [35]. The addition of a spacer of eight 
PEG blocks to compstatin analogs was deemed necessary for 
the SPR binding experiments to increase the space between 
the peptides and attachment to the streptavidin sensor chip 
via lysine–biotin binding. This spacer aimed to increase 
the mobility of the peptides, enhance their accessibility to 
C3, and decrease non-specific interactions, thus emulating 
unbound ligand states as closely as possible within the 
experimental constraints. The inhibitory activities of peptides 
with the same sequences, but without the PEG blocks, were 
tested using ELISAs in the same study [35]. PEGylation is 
an established procedure in drug design and delivery, as this 
procedure has been shown to increase aqueous solubility and 
bioavailability, including enhanced structural and chemical 
stability and circulation lifespan, and reduced renal clear-
ance [36]. In addition, PEGylation has a shielding effect on 
drugs, typically reducing drug immunogenicity, antigenicity, 
and toxicity [36]. Currently, there are several PEGylated 
drugs in the clinic, including pegaptanib, which has been 
used for the treatment of age-related macular degeneration 
[37]. PEGylation has also been used in a compstatin variant 
with modified backbone, but in that case, a large (40 kDa) 
Y-shaped PEG structure was attached either at the N- or 
C-terminus [38], compared to the small (423 Da) linear 8-PEG 
block structure attached at the C-terminus in our study.
Figure 1 shows the dose–response curves of the comple-
ment hemolytic assay for the PEGylated Peptide 2 and the 
parent Peptide 1 (positive control). Peptides 1 and 2 have 
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similar IC50 values within the confidence intervals from four 
replicate experiments, and therefore similar potencies (Table 
2).
We then tested our solubility objective. Figure 2A shows 
the difference between the calculated and spectrophoto-
metrically measured (observed) concentrations in the range of 
5–10 mg/ml. The concentration was experimentally measured 
using absorption spectroscopy at 280 nm and calculated 
using the weight per volume values of the dilution series, as 
described in Methods. Peptide 2 is much more soluble than 
Peptide 1 at 5 mg/ml, as the concentration difference is close 
to zero, the expected difference for nearly perfect solubility. 
In addition, Peptide 2 remains soluble up to 10 mg/ml with 
a slight deviation from the difference of zero, whereas the 
difference of Peptide 1 significantly deviates from zero and 
from constancy as the concentration increases. Figure 2B 
shows a different presentation of the same data in the form 
of a correlation plot between the observed and calculated 
peptide concentrations in millimolar. The data for Peptide 
2 show much higher correlation than those for Peptide 1. In 
addition, the fitted straight line of the data for Peptide 2 is 
closer to a straight line with slope 1 that passes through the 
origin (Figure 2B). A straight line with slope 1 represents 
perfect correlation, denoting the highest solubility and the 
lowest aggregation. These data demonstrate that Peptide 2 has 
significantly higher apparent solubility, or significantly lower 
tendency to aggregate, than the parent Peptide 1.
We continued our study by testing the efficacy of 
Peptides 1 and 2 in a human RPE cell–based assay [23], 
which was used in previous optimizations of compstatin 
family peptides [21,22]. This assay is based on a human RPE 
cell culture that mimics the pathophysiology of AMD and can 
be used to interrogate the effects of complement activation 
in AMD pathogenesis. The assay is useful for quantifica-
tion of the effects of inhibitors on complement activation 
mediated by sub-RPE drusen-like deposits, typical of those 
present in early AMD. Figure 3 shows the deposition of 
deposit-associated C5b-9n following the addition of NHS as 
a complement source [21,23]. Exposure of cell-free inserts to 
NHS did not show any evidence of C5b-9n immunoreactivity 
(Appendix 1), indicating that the baseline level of alternative 
pathway activation in NHS does not likely contribute to this 
increased accumulation of sub-C5b-9n. Confocal imaging of 
immunolabeled RPE culture sections (Figure 3) and (decel-
lularized) whole mounts (Appendix 2) revealed that deposit-
associated sub-RPE C5b-9n deposition is inhibited by both 
compstatin peptides. More specifically, quantification of 
Figure 1. Concentration-dependent 
inhibition curves of compstatin 
peptides in four replicate hemolytic 
assay experiments. The plotted data 
represent the mean percent inhibi-
tion ± standard error of the mean 
(SEM). The dashed line intersects 
each inhibition curve at the IC50. 
Peptide 1 is the parent peptide 
(positive control), and Peptide 2 is 
the PEGylated form of the parent 
peptide.
Table 2. ic50 Values from hemolyTic assay.
Peptide Mean IC50 
(μM)
95% Confidence interval
Upper Lower
1 0.97 1.04 0.90
2 0.96 1.14 0.80
IC50: Ligand concentration at 50% maximal inhibition. Data are 
from four replicate experiments (n=4).
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anti-C5b-9 immunofluorescence from whole mounts revealed 
that Peptide 2 causes a remarkable 80% inhibition (p<0.001) 
of complement activation (Figure 4). The inhibitory effect 
of Peptide 2 was significantly greater (p<0.001) than that 
achieved by Peptide 1, which reduced C5b-9n deposition to a 
lesser degree (50%; p<0.001).
In combination, the hemolytic assay, apparent solubility, 
and human RPE cell–based assay data indicate that Peptide 2 
is a more promising compstatin analog for further optimiza-
tion and potential clinical translation, compared to Peptide 1. 
The parent Peptide 1 had emerged to be the best analog until 
now in previous studies, in terms of solubility and affinity 
balance and efficacy of complement inhibition in the human 
RPE cell–based assay (see [21,22] and references therein for 
earlier optimization studies).
To gain insight into the molecular features that contribute 
to the structural stability and solubility of Peptide 2, we 
performed an extended molecular dynamics simulation. 
Figure 5A shows representative conformations from the top 
(highest occupancy) five structural clusters derived from the 
molecular dynamics trajectory, using backbone atom RMSD-
based clustering. These five clusters represent 79% of the 
conformations spanned by the peptide. The PEG8 C-terminal 
extension demonstrates high local f lexibility and global 
mobility, in essence forming a dynamic polar shell around 
Peptide 2. Flexibility and mobility of the PEG8 extension are 
expected, given its polar character and interactions with water 
molecules of the solvent. This dynamic polar shell perhaps 
functions as a shield from self-association and aggregation 
of Peptide 2 owed to peptide’s inherent hydrophobic features, 
thus contributing to the solubility of the peptide.
Figure 5B shows the conformation of the representative 
peptide from the structural cluster with highest occupancy, 
depicting key amino acid side chains for the optimization of 
compstatin from research in the past 20 years. These amino 
acids are Arg(-1), Val3, Trp4, Trp7, Ala9, and the disulfide 
bridge Cys2-Cys12. The Arg(-1) addition corresponds to the 
Arg(-1)/Ser0 extension of Peptide 1 [22], the parent analog 
of Peptide 2. Our latest addition in this work is the PEG8-
NH2 (Figure 5D) extension at the C-terminus (Figure 5A–C), 
which results in Peptide 2, our most promising, in terms of 
affinity and solubility properties, lead peptide of the comp-
statin family until now.
Figure 2. Apparent solubility of compstatin peptides. A: The difference in concentration, calculated – observed (measured), in mM, plotted 
against the expected concentration (in mg/ml). The actual observables are plotted, the expected concentration (in mg/ml) of the dilution 
series on the horizontal axis, and the observed (in mM, measured using tryptophan absorbance) minus the calculated (in mM, from the 
mg/ml expected concentration values) on the vertical axis. Peptide 2 is the most soluble, as the concentration difference is close to zero 
and remains nearly constant in the dilution series. B: Correlation of the observed concentration with the calculated concentration, with the 
concentrations presented in mM. Peptide 2 is the most soluble, as indicated by the high correlation between the observed and calculated 
concentrations (slope of 0.92). Each data point represents the mean measured concentration and the corresponding expected concentration 
with a linear regression fit to the data. A straight line of slope 1 passing through the origin is inserted to indicate the closeness of the data 
to perfect correlation.
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Figure 3. Human RPE cells form basal deposits rich in C5b-9n (MAC) in vitro, and inhibitory effects of compstatin peptides. Representative 
cross-sectional images show 3-month-old RPE cell cultures labeled with anti-C5b-9n (green) and 4',6-diamidino-2-phenylindole (DAPI; 
blue), following exposure to either 10% normal human serum (NHS) alone or together with Peptides 1 and 2 for 24 h. Cultures that received 
no NHS treatment served as negative control. Scale bar = 10 μm.
Figure 4. Compstatin peptides 
inhibit complement-induced C5b-9n 
deposition in RPE culture. Fluores-
cence intensity measurements from 
anti-C5b-9n-labeled (decellularized) 
whole mount samples (n ≥ 9) were 
normalized human serum (NHS)-
treated samples and plotted as mean 
± standard error of the mean (SEM). 
Data analyses show that Peptide 
2 causes 80% reduction in NHS-
induced basal C5b-9n deposition 
by RPE cells. Peptide 1 exhibits a 
weaker inhibitory effect, reducing 
C5b-9n deposition by 50%. Bars 
indicate mean ± SEM.
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DISCUSSION
We report the design of a new compstatin peptide that has 
superior aqueous solubility and comparable complement 
inhibitory activity characteristics, compared to previously 
known peptides of the compstatin family. The new peptide, 
Peptide 2 (Table 1), is a PEGylated form of our previously 
most promising peptide in terms of inhibitory activity and 
aqueous solubility, Peptide 1 (Table 1) [22]. Peptide 2 has eight 
PEG blocks attached to the backbone C-terminus, accounting 
for an additional molecular mass of 423 Da compared to 
Peptide 1 (Table 1). Since the original discovery of comp-
statin using a phage-displayed random peptide library [39], 
there have been many benchmarks in the optimization of the 
sequence of compstatin. Initial structure-activity studies had 
derived a sequence template with seven amino acids being 
indispensable for inhibitory activity and six amino acids 
being optimizable [17,40]. Figure 5B shows the side chains of 
essential amino acids for the optimal binding and inhibitory 
activity of compstatin, including benchmark residue-specific 
optimization steps over the period of several years. Initial 
NMR, alanine scan, and inhibitory activity studies indicated 
that Val3 and Trp7 are important for binding to C3 and 
inhibition of complement activation [41,42]. A subsequent 
crystal structure of C3c in complex with a compstatin analog 
confirmed these findings, showing that Val3 and Trp7 are 
inserted in hydrophobic cavities [30]. Benchmark optimiza-
tion steps include the incorporation of (i) Ala at position 9, 
which introduces helicity in the sequence and shifts a struc-
tural beta-turn from the central toward the C-terminal portion 
of the sequence [41,42]; (ii) aromatic amino acids at position 4 
[16] with Trp4 being optimal [18], which was shown to partic-
ipate in a hydrophobic clustering in the crystal structure [30]; 
(iii) dipeptide N-terminal extensions, with Arg at position 
−1 being optimal because it increased solubility compared 
to previous peptides and introduced a new intermolecular 
salt bridge as shown by molecular dynamics simulations 
[21,22]; and in this work, (iv) C-terminal extension using an 
eight-block PEG construct, which greatly increases aqueous 
solubility, unprecedented by any other compstatin analog. In 
Figure 5. Molecular structure of Peptide 2. A: Representative conformers of Peptide 2 from the five highest-populated root-mean-square 
deviation (RMSD) clusters of the molecular dynamics trajectory, with occupancies of 38%, 12%, 10%, 10%, and 9%. The peptide backbone 
is shown in a tube representation, colored by the amino acid property type: gray for hydrophobic, green for polar, and brown for glycine. 
Cys2 and Cys12 are marked as hydrophobic because they form a disulfide bridge. The PEG8 C-terminal extensions are shown in stick 
models of different colors for each conformer. The acetyl and amide terminal blocks are shown in stick models, colored by atom type: gray 
for carbon, white for hydrogen, blue for nitrogen, and red for oxygen. B: The major conformer of Peptide 2 (38% occupancy) in backbone 
tube representation, with key side chains in compstatin peptide optimization in stick representation. The location of all amino acids is 
marked. The following color code is used: gray for hydrophobic, green for polar neutral, blue for basic, red for acidic, yellow for cysteines 
and the disulfide bridge, and brown for glycine. The PEG8-NH2 C-terminal extension is shown in stick representation without hydrogens, 
with carbons depicted in brown, oxygens in red, and nitrogen in blue. C: Surface representation of Peptide 2, with the PEG8-NH2 extension 
shown in stick representation (including hydrogens). The color code is as in Panel B, with the added hydrogens of PEG8-NH2 shown in white. 
D: The chemical structure of PEG8-NH2.
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addition, acetylation at the N-terminus and amidation at the 
C-terminus contribute to improved activity [43]. All active 
peptides contain a Cys2-Cys12 disulfide bridge.
Compstatin has two surfaces, a hydrophobic and a polar 
one, as was pointed out by the original NMR studies [41,42], 
but it is the hydrophobic surface that makes the main contacts 
with the C3, as it was pointed out by the crystal structure 
[30]. It is likely that the hydrophobic surface is responsible 
for the aggregation properties of the compstatin analog that 
underwent the early clinical trials. This analog contained a 
methylated Trp4 residue, in which the hydrophobic methyl 
group had replaced the polar hydrogen of the indole amide 
group, making the peptide even more hydrophobic. We had 
reasoned in earlier optimization studies that incorporation 
of polar amino acid extensions at the termini would increase 
solubility without perturbing binding properties, and this 
was shown to be the case for the N-terminus [21,22] and 
C-terminus (Mohan RR, Gorham RD Jr, Morikis D, unpub-
lished data). However, the analog with the best aqueous solu-
bility is Peptide 2 of this work that incorporates an 8-PEG 
block construct at the C-terminus. Our earlier molecular 
dynamics studies had shown that the C-terminus is mobile 
pointing outward from the C3-peptide interface toward the 
solvent. Thus, we reasoned that the 8-PEG block construct 
would not sterically interfere with the binding interface of 
the C3-peptide complex. This is evident in Figure 5, where 
the 8-PEG construct shows mobility around the non-binding 
site of Peptide 2, without specific contacts with the peptide. 
Therefore, PEGylation acts a solubilizer of compstatin.
To determine the potential of Peptide 2 and its parent 
Peptide 1 as AMD therapeutics, we evaluated the peptides 
in the human RPE cell–based assay. As we have reported 
before [36], this in vitro assay is characterized by the forma-
tion of C5b-9-rich sub-RPE deposits, a hallmark of dry AMD. 
Thus, this assay represents a unique testbed for screening 
therapeutic candidates for treatment of dry AMD. We have 
successfully used this assay for our recent optimization 
studies that resulted in the incorporation of polar N-terminal 
extensions in our compstatin analogs [21,22]. Here, we use 
this assay to demonstrate that Peptides 1 and 2 significantly 
inhibit the formation of C5b-9-rich sub-RPE deposits, 
with the PEGylated Peptide 2 exhibiting a twofold greater 
inhibitory effect than the parent Peptide 1. This difference 
in anti-C5b-9 effect may be attributed to lack of aggrega-
tion of Peptide 2, owing to its greater solubility compared to 
Peptide 1, which is expected to result in a higher “effective” 
concentration in the RPE culture. At the molecular level, the 
optimal solubility of Peptide 2 results from the formation 
of a dynamic polar shell, introduced by PEGylation, which 
predominantly surrounds and enhances the polar surface, and 
to a lesser extent the nonpolar surface of the peptide. This 
polar shell is designed to be a solubilizer, shielding Peptide 
2 from self-association and higher-order aggregation, while 
leaving it unobstructed for binding the nonpolar surface.
In conclusion, we report the design of a new peptide 
analog of compstatin that combines an arginine-serine 
N-terminal polar amino acid extension and an 8-PEG block 
C-terminal extension. This peptide demonstrates signifi-
cantly improved aqueous solubility and efficacy in a human 
RPE cell–based assay that mimics the pathobiology of AMD, 
compared to its parent peptide, while retaining comparable 
inhibitory activity against complement activation as its parent 
peptide. The new peptide can lead to a therapeutic treatment 
of dry AMD, as the peptide overcomes the aggregation limi-
tation of a previous compstatin analog that underwent clinical 
trials.
APPENDIX 1.
Representative whole-mount images show ‘cell-free’ culture 
inserts labeled with anti-C5b-9n (green) following exposure to 
10% NHS for 24h. No evidence of C5b-9n immunoreactivity 
is seen in the absence of RPE cells. To access the data, click 
or select the words “Appendix 1.”
APPENDIX 2.
Representative whole-mount images show two month-old 
RPE cell cultures labeled with anti-C5b-9n (green) following 
exposure to either 10% NHS alone or together with peptides 
1 and 2 for 24h. Cultures that received no NHS treatment 
served as negative control. Scale bar: 25 μm. To access the 
data, click or select the words “Appendix 2.”
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